Vector BioPharma

Vector BioPharma is a Swiss-based biotechnology company pioneering targeted gene delivery technologies to enhance precision in cell and gene therapy. The company was spun out of ETH Zurich and is built around novel high-capacity viral vectors designed to deliver therapeutic payloads selectively to specific cell types. Unlike traditional viral vectors that rely on naturally evolved tropism, Vector BioPharma employs a modular capsid architecture with engineered targeting ligands, allowing precise control over tissue specificity and immune evasion.

The company’s lead platform, VECTOR™, integrates two core innovations: a high-capacity, genome-scale payload capability and customizable tropism via designed protein ligands. This enables both large-scale genomic interventions—such as the delivery of entire gene loci or complex regulatory networks—and targeting of tissues that are traditionally inaccessible to existing vectors, such as certain solid tumors or fibrotic organs.

Vector BioPharma’s approach also addresses key challenges in the gene therapy space: off-target effects, pre-existing immunity to viral capsids, and limited payload size. By enabling more precise and durable expression of therapeutic genes, the company is positioning its technology for a broad range of applications, including oncology, metabolic diseases, and regenerative medicine.

The firm has received substantial backing from leading life sciences investors and maintains research and development collaborations with academic and industry partners to advance its pipeline and platform technologies.

Keywords: Vector BioPharma, gene therapy, targeted delivery, viral vector, high-capacity vector, ETH Zurich, cell-specific targeting, VECTOR platform, precision medicine, biotechnology, payload delivery, engineered capsid, tropism design, immune evasion